Home Versus Hospital Treatment With Bypassing Agent: An Economic Analysis
Back to listAdded: 30 November 2011
Introduction
The development of inhibitory antibodies to factor VIII (FVIII) or factor IX (FIX) is a serious complication of hemophilia. Activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) are used as hemostatic bypassing agents in treating patients with inhibitors 2. The mechanism is not fully understood; however, aPCC (FEIBA, Baxter AG, Vienna, Austria) and rFVIIa (NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) are able to bypass the FVIII-dependent step in the coagulation cascade and promote hemostasis by enhancing thrombin generation 3.
Abstract
Keywords
economic analysis, aPCC, FVIII inhibitor, home treatment, Hemophilia A with inhibitors
Other Articles
- Effect of Adjusted and Non-Adjusted Citrate Concentrations on Coagulation Test Results in Patients With High Hematocrit Values—Breaking the Unproven Leap of Faith
- The Off-Label Use of Recombinant FVIIa in the Treatment of a Patient With T-Cell Non-Hodgkin Lymphoma Who Developed Intra-abdominal and Intra-Pleural Hemorrhages Followed by High-Dose Methotreaxate Therapy
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors